Form 8-K

8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities and Exchange Act of 1934

Date of Report (Date of earliest reported event): March 28, 2005

GEOPHARMA, INC.

(Exact name of registrant as specified in charter)

Florida

001-16185

59-2600232

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)


6950 Bryan Dairy Road, Largo, Florida		33777
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (727) 544-8866

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On March 28, 2005, the Board of Directors of GeoPharma, Inc. (the “Company”), appointed Carol Dore-Falcone to be a member of the Board. Ms. Dore-Falcone has served as our Vice President and Chief Financial Officer since August 1999. She also served as Vice President and Chief Financial Officer of Dynamic Health Products, Inc. from August 1999 until November 7, 2000. Prior to joining us, Ms. Dore-Falcone was employed as an audit manager with Deloitte & Touche, Certified Public Accountants, where she had served in various capacities since January 1990. Ms. Dore-Falcone is a certified public accountant and holds an M.B.A. from the University of Tampa. Ms. Dore-Falcone will not be appointed to any committees of the Board at this time.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		GEOPHARMA, INC.

Date: March 30, 2005		/s/ Mihir K. Taneja
		Mihir K. Taneja, Chief Executive Officer

		/s/ Carol Dore-Falcone
		Carol Dore-Falcone, Vice President and Chief Financial Officer